Robotic - assisted coronary angioplasties a solution today for hospitals across the country
Waltham, MA – July 23, 2014 – As attention increases on the effects of radiation exposure among interventional cardiologists1, Corindus Vascular Robotics announced the recent installations of its CorPath® System at five facilities: UH Case Medical Center, Cleveland, OH; Virginia Commonwealth University Medical Center, Richmond, VA; Miami Cardiac & Vascular Institute, Miami, FL; the second system in Michigan and first system in North Carolina. In addition, Corindus announced that customers used the CorPath System in a record number of cases in the quarter ending June 2014, the third straight quarter of record - setting utilization. The consistent increase in utilization demonstrates that customers continue to make CorPath the standard of care for PCI.
Corindus’ CorPath System is the first FDA - cleared medical device to bring robotic - assisted precision and accuracy to coronary angioplasty procedures. During a CorPath Robotic Angioplasty procedure, the interventional cardiologist sits in the radiation shielded interventional cockpit, and advances stents and guidewires with millimeter by millimeter precision. Robotic angioplasty may improve stent placement which can reduce repeat procedures. The CorPath System also reduces physician radiation exposure during procedures by 95 percent2.
“We use the CorPath System on a daily basis at our facility. We even use the CorPath System as a tool with appropriate complex PCI cases, and continue to see and feel the benefits of robotic precision, along with radiation protection for the physician,” said Daniel Simon, MD, Director, Harrington Heart & Vascular Institute, UH Case Medical Center.
“The threat of radiation exposure and musculoskeletal disorders for interventional cardiologists is poised to become a pivotal industry issue as emerging studies continue to point to a real need for protecting clinicians in the cath lab,” said David Handler, President and CEO of Corindus Vascular Robotics. “We continue to meet with hospital executives who understand the potential cost and risk that radiation poses to their staff, and who see the CorPath System as a way to not only benefit patients, but their physicians as well.”
As a leader in the robotic space, Corindus has seen the number of customer installs grow across the country, and several customers have recently added second systems to their facility to provide Robotic Angioplasty for more patients and physicians.
Corindus recently exhibited at the Society for Cardiovascular Angiography and Interventions (SCAI) 2014 annual scientific session, where more than 60 physicians attended a breakfast symposium sponsored by Corindus. Five current users spoke about their experience with CorPath and the benefits they derive from the implementation of robotic angioplasty.
For more information, visit www.corindus.com.
1Wood, Shelley. “Climbing Head and Neck Tumor Count in Interventional Cardiologists Prompts Calls for More Study,” MedScape.com, 23 April 2014, http://www.medscape.com/viewarticle/824022
2Weisz, G. et al. Safety and Feasibility of Robotic Percutaneous Coronary Intervention: PRECISE (Percutaneous Robotically-Enhanced Coronary Intervention) Study. J Am Coll Cardiol. 2013;61(15):1596-1600.
Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath System is the first FDA-cleared medical device to bring robotic precision to interventional procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program."
For additional information, visit www.corindus.com, and follow @CorindusInc.
Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future event
Examples of such statements include statements: